# RNN 1st Gen Model Celgene Corporation Pharmaceutical preparations

Stock predictor AI models:
78.05% successful of 82 deals
$ 108.24 Last close price
at 22-nov-2019


Model's trade recommendations 2.98% Return for period

12.51% Annual return

$63.12B Market Cap

β 1.49  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 2.98%
52wk return 0.46%
52wk Range
Sortino ratio 1.28
Sharpe ratio 0.99
Norm. RMSE 0.37%
Downside risk 9.56%
Volatility 0.00%
  • BUY Analysts consensus recommendation

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Celgene Corporation (CELG) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for CELG model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for CELG.

Model is being retrained on a daily basis.

Float 719M
P/E 12.67
Shares Outstanding 726M
% Held by Insiders 0.95%
% Held by Institutions 78.42%
EPS (last reported FY) $6.84
EPS (last reported Q) $1.87
EPS, estimated (last reported Q) $1.78
Total revenues $13 B
Net income $3 B